Sovereign Nations. Different Laws. One Complicated Payments System.
Sovereign Nations. Different Laws. One Complicated Payments System. On Indigenous Peoples' Day, it's time to examine why tribal gaming, ...
The functional mushroom category has a documentation problem. Retailers are pulling products over ingredient permissibility questions. The FDA has issued warning letters citing claims that could not be substantiated against what was actually in the product. A pending citizen petition asks the agency to require that mushroom supplement labels distinguish between fruiting body and mycelium — a distinction with direct consequences for the potency claims brands are making. Across all of it, the through-line is the same: the COA is not doing enough work.
A Certificate of Analysis is the foundational document connecting what a brand claims its product contains to what actually went into it. In the functional mushroom space, that connection is frequently weak, inconsistently managed, and poorly organized for the regulatory and commercial scrutiny it now faces.
Most mushroom supplement COAs confirm identity and absence of common contaminants — heavy metals, pesticides, microbial pathogens. That is a starting point, not a complete picture.
The Functional Mushroom Council and ingredient suppliers have repeatedly flagged that lion's mane, reishi, chaga, cordyceps, and turkey tail each contain distinct bioactive compound profiles that determine how they perform and what claims can be substantiated. Beta-glucans — polysaccharides linked to immune and metabolic function — are the primary marker compound for most functional mushroom testing. A COA that confirms species identity but does not verify batch-specific beta-glucan concentration provides the brand with no defensible basis for immune support claims.
Beyond beta-glucans, the fruiting body versus mycelium distinction matters for specific compounds. Erinacines, which are found primarily in the mycelium of lion's mane and have been the focus of cognitive health research, are not present in fruiting body extracts at meaningful levels. A product label that says "lion's mane extract" without specifying which part of the organism was used, and a COA that does not verify the relevant active compound, leaves a gap between what the consumer believes they are buying and what they are actually getting.
That gap is not invisible. It is exactly what plaintiffs' attorneys look for in supplement class action litigation, and it is what the FDA found when it reviewed products whose claims were not supportable by the ingredients as formulated.
Premium natural retailers have moved faster than federal regulators on ingredient documentation requirements. A mushroom supplement brand seeking shelf placement in major specialty retail chains faces ingredient permissibility questions, COA verification demands, and in some cases requests for GRAS substantiation for food and beverage formats — documentation that the FDA itself rarely requests upfront but that retailers treat as a prerequisite.
A COA issued at the time of ingredient sourcing and never revisited does not satisfy this standard. Retailers want batch-level documentation, meaning each production run has a corresponding COA that verifies identity and active compound concentrations for that specific batch. A single COA filed at product launch and cited for all subsequent inventory is not a documentation system — it is a gap waiting to be discovered.
Functional mushroom ingredients are sourced globally, with a significant portion coming from suppliers in China and other international markets. The variability in cultivation conditions, substrate materials, and extraction methods between suppliers means that the active compound profile of ostensibly the same ingredient can differ substantially across sources.
A brand that switches mushroom extract suppliers — or whose supplier changes their cultivation process — without updating and verifying their COA documentation is carrying risk they may not know about. Claims built on the original supplier's testing data no longer apply to the product in the bottle. When that mismatch surfaces in a regulatory inspection, a retail audit, or a consumer complaint, the documentation gap becomes an enforcement and liability problem.
Batch-level COA documentation is the minimum. Each production run should have a corresponding COA that confirms species identity, part used (fruiting body, mycelium, or specified ratio), active compound concentrations, and contaminant testing results. That COA should be accessible, retrievable, and traceable to the specific product lot in distribution.
For brands selling into food and beverage formats, the COA documentation needs to be paired with a defensible GRAS position for each ingredient under its specific conditions of use. Testing that qualifies an ingredient for capsule supplement use does not automatically extend to ready-to-drink mushroom coffee or functional gummies.
The documentation burden is ongoing, not a one-time event. Supplier qualification, incoming material testing, in-process controls, and finished product verification each generate records that need to be organized, maintained, and retrievable. Manual COA management — spreadsheets, email attachments, PDFs filed without version control — creates exactly the kind of fragmented record that fails under scrutiny.
Contact Qredible today to learn how MyCOA, our blockchain-secured COA management platform, helps functional mushroom and botanical supplement businesses implement batch-level documentation systems, maintain tamper-proof ingredient verification records, and build the supply chain transparency infrastructure that regulators, retailers, and financial partners require.
